Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H28ClN3O2S |
Molecular Weight | 446.005 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
InChI
InChIKey=AIUHRQHVWSUTGJ-UHFFFAOYSA-N
InChI=1S/C23H28ClN3O2S/c1-18(28)29-16-15-26-13-11-25(12-14-26)9-4-10-27-20-5-2-3-6-22(20)30-23-8-7-19(24)17-21(23)27/h2-3,5-8,17H,4,9-16H2,1H3
Molecular Formula | C23H28ClN3O2S |
Molecular Weight | 446.005 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 33 - 60 n = 10 Health Status: unhealthy Condition: Huntington’s chorea Age Group: 33 - 60 Sex: M+F Population Size: 10 Sources: Page: p.105 |
Disc. AE: Parkinsonism... AEs leading to discontinuation/dose reduction: Parkinsonism (10%) Sources: Page: p.105 |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.578 |
unhealthy, 39 - 69 n = 15 Health Status: unhealthy Condition: Tardive dyskinesia Age Group: 39 - 69 Sex: M+F Population Size: 15 Sources: Page: p.578 |
Disc. AE: Parkinsonism... AEs leading to discontinuation/dose reduction: Parkinsonism (20%) Sources: Page: p.578 |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.100 |
unhealthy, 44 - 70 n = 4 Health Status: unhealthy Condition: Tardive dyskinesia Age Group: 44 - 70 Sex: M+F Population Size: 4 Sources: Page: p.100 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Parkinsonism | 10% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 33 - 60 n = 10 Health Status: unhealthy Condition: Huntington’s chorea Age Group: 33 - 60 Sex: M+F Population Size: 10 Sources: Page: p.105 |
Parkinsonism | 20% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.578 |
unhealthy, 39 - 69 n = 15 Health Status: unhealthy Condition: Tardive dyskinesia Age Group: 39 - 69 Sex: M+F Population Size: 15 Sources: Page: p.578 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:32:19 GMT 2023
by
admin
on
Fri Dec 15 15:32:19 GMT 2023
|
Record UNII |
0JFY081Q2X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05AB05
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
||
|
WHO-VATC |
QN05AB05
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
||
|
NCI_THESAURUS |
C740
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3401
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
DTXSID6023654
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
C100194
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
SUB10982MIG
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
100000082146
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
38133
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
C152590
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697851
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
201-513-4
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
59119
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
2634
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
84-06-0
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
m10779
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
742
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
6762
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
0JFY081Q2X
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
DB13557
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
Thiopropazate
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |